ReviewCurrent pharmaceutical biotechnology2026
Dendrimers-based Hydrogels and Nanogels for Drug Delivery.
Review in Current pharmaceutical biotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Functional Self-Immolative Hydrogels with Dendritic Cross-Linkers for Controlled Drug Delivery.Chemistry of materials : a publication of the American Chemical Society · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Current developments in nanotechnology provide an alternative therapy for various diseases by utilizing customized medicine. Among some of the nanoscale superstructures made of the hydrophilic or amphiphilic polymeric matrix are nanogels. At the same time, hydrogels are the first biomaterials created for insertion into the human body and have several biological uses. Owing to the advantages of nanogels and hydrogel, including biocompatibility, hydrophilicity, controlled drug release, and intelligent drug delivery, another macromolecule called dendrimer is incorporated into the nanogel and hydrogel for synergistic effects. In this review, we focus on the applications of dendrimer-based hydrogels and nanogels as carriers for targeted delivery of drugs. We also present the synthetic processes, different characterization methods, and challenges in incorporating the dendrimer and the drug during the preparation of nanogel and hydrogel. In recent years, the most widely used dendrimers for hydrogel formation have been reported to be poly(amidoamine) (PAMAM), phosphorous, peptide, and polyester dendrimers. Dendrimer-based hydrogel and nanogels show various applications in the treatment of a wide range of diseases, such as glaucoma, cancer, and microbial diseases. The self-cleaving mechanism of dendrimer hydrogels (DH) leads to enhanced and sustained delivery of the drugs in the treatment of cancer. Recent studies show the use of doxorubicinconjugated nanogel-based PAMAM dendrimer as a capable nanocarrier for the delivery of drugs in the treatment of cancer.
Indexed as
Identifiers
40192042What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.